{"podcast":{"title":"Gynecologic Oncology Update","slug":"gynecologic-oncology-update-612940","podcast_index_feed_id":612940,"rss_url":"https://feeds.captivate.fm/gynecologic-oncology/","website_url":"https://www.researchtopractice.com/browse-tumor-types/ovarian-cancer","image_url":"https://artwork.captivate.fm/aa2bde68-0d40-4e41-b73e-fff33f9524cf/gou-podcast-logo-3000px.png","author":"Dr. Neil Love","episode_count":52,"summary":"This series bridges the gap between research and patient care by providing medical and gynecologic oncologists with access to the latest research developments and expert perspectives on up-to-date clinical management strategies for gynecologic cancers.","last_synced_at":"2026-09-18T02:23:24.296340+00:00","page_url":"https://stenobird.com/podcast/gynecologic-oncology-update-612940"},"episode":{"title":"TROP2- and CDH6-Directed ADCs in Gynecologic Cancers — An Interview with Dr Ramez Eskander on Key Presentations from the Society of Gynecologic Oncology 2026 Annual Meeting","slug":"trop2-and-cdh6-directed-adcs-in-gynecologic-cancers-an-interview-with-dr-ramez-eskander-on-key-presentations-from-the-society-of-gynecologic-oncology-2026-annual-meeting","published_at":"2026-08-01T13:00:00+00:00","page_url":"https://stenobird.com/podcast/gynecologic-oncology-update-612940/trop2-and-cdh6-directed-adcs-in-gynecologic-cancers-an-interview-with-dr-ramez-eskander-on-key-presentations-from-the-society-of-gynecologic-oncology-2026-annual-meeting","show_page_url":"https://stenobird.com/podcast/gynecologic-oncology-update-612940","url":"https://gynecologic-oncology.captivate.fm/episode/5988-sgo26-review-adcsgyn","audio_url":"https://dts.podtrac.com/redirect.mp3/episodes.captivate.fm/episode/d55eeff4-01ab-41e2-b9a1-5353ebd3dc6d.mp3","summary":"Featuring an interview with Dr Ramez Eskander, including the following topics: Overview of antibody-drug conjugates (ADCs) and their role in the management of gynecologic cancers; considerations in sequencing (0:00) Choosing between FRɑ- and HER2-directed ADCs for dually eligible patients; role of antigenic target in predicting efficacy benefit of ADCs (7:53) Comparative efficacy and safety of ADCs and conventional chemotherapy (12:58) Current and investigational targets of ADCs in gynecologic cancers (17:14) Current research surrounding raludotatug deruxtecan (R-DXd) and its potential role in clinical practice (21:56) Safety and tolerability profiles of ADCs, including R-DXd, and potential mitigation strategies (27:36) Overview of available TROP2-directed ADCs for gynecologic cancers, including key clinical data (33:34) Evolving use of TROP2-directed ADCs for gynecologic cancers in clinical trials (39:05) Oral mucositis/stomatitis associated with TROP2-directed ADCs and potential mitigation strategies (44:38) CME information and select publications","meta_description":"Featuring an interview with Dr Ramez Eskander, including the following topics: Overview of antibody-drug conjugates (ADCs) and their role in the managemen…","key_points":[],"chapters":[],"topics":[],"duration_seconds":3284,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/gynecologic-oncology-update-612940/episodes/trop2-and-cdh6-directed-adcs-in-gynecologic-cancers-an-interview-with-dr-ramez-eskander-on-key-presentations-from-the-society-of-gynecologic-oncology-2026-annual-meeting/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/gynecologic-oncology-update-612940/trop2-and-cdh6-directed-adcs-in-gynecologic-cancers-an-interview-with-dr-ramez-eskander-on-key-presentations-from-the-society-of-gynecologic-oncology-2026-annual-meeting.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}